OF ALL THE medical challenges that scientists have confronted, Alzheimer’s illness, the commonest type of dementia, has been one of many trickiest. Between 1995 and 2021 personal cash spent on Alzheimer’s analysis totalled $42.5bn, however greater than 140 trials didn’t ship a single drug able to slowing the illness. But the tide could also be turning. There are two working medicine, providing modest advantages, in the marketplace. A brand new overview paper suggests extra might quickly comply with.
